Microplastics Have a Concerning Effect on The Microbes in Our Gut
The study was led by researchers from the National Cheng Kung University in Taiwan, who fed mice polystyrene nanoplastics for 12 weeks. Nanoplastics are the smallest type of microplastic, and in these experiments the fragments were just 100 nanometers in size, thousands of times smaller than the width of a human hair.
Careful analysis of the animals revealed subsequent changes to protein production, gene activity, bacteria levels, and the microRNA coding inside cells. For example, two proteins that normally keep the gut sealed and protected became less abundant.
The beneficial bacteria Lactobacillus decreased, the potentially harmful bacteria Ruminococcaceae increased, and a bacteria called Lachnospiraceae actually ate some of the nanoplastics.
Doing so changed the way the bacteria secreted tiny packages called extracellular vesicles, which in turn inhibited the production of intestinal mucus.
"This study is the first to show that plastic particles can interfere with the microRNA carried by extracellular vesicles between mouse intestinal cells and specific gut microbes, disrupting host–microbe communication and altering microbial composition in ways that may harm the gut health of mice," says microbiologist Wei-Hsuan Hsu, from the National Cheng Kung University.
For those of us who aren't biologists, these changes can be hard to interpret in a simple way, but overall the integrity and health of the guts of the mice took a turn for the worse. It's likely that the risk of related health complications would go up as a result.
In this study, the mechanisms behind how nanoplastics affect the gut are just as important as the effects themselves, and will now point researchers towards new approaches for understanding how microplastics might alter our bodies on a fundamental level.
"The research identifies a molecular mechanism by which plastic particles disturb gut microbiota," says Hsu.
It's important to add some context to this study. Mice are useful substitutes for humans in research, but they're obviously not an exact match, so we need to see if similar gut changes come about in people.
What's more, the mice were fed nanoplastics at a much higher level than humans would usually be exposed to. It's not clear if we are ingesting anywhere near enough plastic to trigger the changes shown in this study.
Even with those limitations in mind, though, the research raises some real concerns over microplastics and health. More data is needed on our exposure to these tiny plastic fragments, and the subsequent effects.
"Given the current limitations in nanoplastic detection technologies and the uncertainties associated with extrapolating animal model results to humans, continued research is critical to accurately evaluate the potential long-term health effects of nanoplastics in humans," says immunologist Yueh-Hsia Luo, from the National Central University in Taiwan, who wasn't involved in the study.
The research has been published in Nature Communications.
Something in Your Poop May Predict an Imminent Death
Long-Term Contraceptive Pill Use Linked With Brain Tumor Risk
Just One Night of Poor Sleep Can Change How Your Brain Sees Food
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Diamonds could help detect cancer using groundbreaking new technique
Scientists have developed a diamond-based sensor that could make it easier for doctors to detect the spread of cancer. Researchers at the University of Warwick have created a handheld device that is designed to trace tiny magnetic particles injected into the body. The scientists said this offers a non-toxic alternative to radioactive tracers and dyes currently used in hospitals. Metastasis, when cancer cells spread from the original tumour to other parts of the body, is one of the most serious challenges in cancer treatment. Doctors often rely on tests to see whether the cancer has reached the lymph nodes – the areas of tissue that filter fluid in your body for harmful substances – which can guide decisions about surgery and further care. The findings, published in Physical Review Applied, describe how diamonds can be used to build a highly sensitive sensor capable of identifying the magnetic tracer fluid injected into a tumour. This fluid, made up of iron oxide nanoparticles, travels through the body alongside cancer cells, revealing whether they have reached the lymph nodes, the researchers said. Lead author Alex Newman, a PhD student in Warwick University's physics department, said the new tool could improve the way doctors find cancer in keyhole and endoscopic surgery. 'There is a real demand for versatile non-toxic means of finding cancer,' he said. 'For this new diamond-based sensor, we managed to get the size of the sensor head down to just 10 millimetres, which means it is the first diamond sensor to be able to detect magnetic tracer fluid while being small enough for endoscopic use and keyhole surgery.' Mr Newman added that the device was extremely sensitive, capable of detecting just one hundredth of the typical dose of magnetic tracer fluid. The design uses a diamond measuring only half a cubic millimetre alongside a small permanent magnet, the scientists said They added that this compact structure means there is no need for bulky electronics, allowing the sensor to be used by hand in operating rooms. Professor Gavin Morley, who leads the research group, said the breakthrough was possible thanks to nitrogen vacancy centres inside the diamond. 'These allow the diamond to detect very small changes in the magnetic field and give the diamonds a lovely pink colour,' he said. He added that the technology could also have uses beyond medicine, including in spacecraft and fusion power. Current techniques for tracing cancer cells rely on radioactive tracers, which not all hospitals can access, or blue dyes, which trigger allergic reactions in some patients, the researchers said. Clinicians involved in this new project believe the new diamond sensor could help avoid these complications. Stuart Robertson, a consultant breast cancer surgeon at University Hospitals Coventry and Warwickshire, said he was already using magnetic localisation in his work. He added that it offers more advantages over traditional techniques. Researchers say the device could eventually be applied to various cancers, including lung, liver, colorectal and oesophageal tumours.
Medscape
27 minutes ago
- Medscape
Prenatal Metformin Shows Mixed Effects in PCOS
TOPLINE: Women with polycystic ovary syndrome (PCOS) who received metformin during pregnancy experienced a reduced rate of maternal infections, particularly viral infections. However, offsprings who were exposed to metformin in utero faced a high long-term risk for allergies and eczema. METHODOLOGY: Researchers in Norway conducted post hoc analyses of two randomised controlled trials and one follow-up study to examine immunologic effects of metformin in pregnant women with PCOS and in offsprings exposed to the medication in utero. They analysed the data of 634 pregnant women with PCOS who had been randomly assigned to receive either metformin (n = 316; median age, 30 years) or placebo (n = 332; median age, 30 years) from the first trimester to delivery. The effect of metformin exposure in utero was studied in 145 offsprings, with 74 and 71 being exposed to metformin and placebo in utero, respectively. Maternal clinical evaluations were performed at baseline and at regular intervals through gestational week 36, with self-reported maternal infections being recorded throughout pregnancy, delivery, and postpartum. Offsprings were evaluated for the diagnosis of any allergic condition such as asthma or eczema at a median age of nearly 8 years. TAKEAWAY: Women receiving metformin had fewer overall infections during pregnancy than those receiving placebo (odds ratio [OR], 0.68; 95% CI, 0.50-0.93), particularly viral infections (OR, 0.71; 95% CI, 0.51-0.99); the protective effect of metformin against viral infections was significant among women with obesity alone. Offsprings exposed to metformin in utero showed higher rates of allergy (OR, 4.83; 95% CI, 1.47-21.8) and eczema (OR, 2.42; 95% CI, 1.14-5.33) than those exposed to placebo in utero. Neither offspring BMI nor maternal infections during pregnancy modified the association between prenatal metformin exposure and the elevated risk for allergic conditions in offsprings. IN PRACTICE: "In the present study, metformin reduced the incidence of maternal infections during pregnancy while it increased the incidence of eczema and allergies in the offspring, suggesting that maternal infections might act as a protective factor," the authors wrote. "The adverse effects observed in the offspring highlight the need for caution when considering metformin treatment during pregnancy," they added. SOURCE: This study was led by Mariell Ryssdal, Norwegian University of Science and Technology, Trondheim, Norway. It was published online on August 11, 2025, in BJOG: An International Journal of Obstetrics & Gynaecology. LIMITATIONS: The original studies were not designed to assess metformin's effects on infections or allergic diseases. Maternal infections were self-reported and classified on the basis of symptoms without pathogen confirmation. Asthma, eczema, and allergies were diagnosed by doctors but reported by mothers without verification through medical tests. DISCLOSURES: This study was supported by The Liaison Committee for Education, Research, and Innovation in Central Norway; The Research Council of Norway; Novo Nordisk Foundation; and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
27 minutes ago
- Medscape
Nutrition Status Predicts Frailty in Patients With HF
TOPLINE: A substantial proportion of patients hospitalised with chronic heart failure (HF) were at risk for malnutrition, which was associated with elevated odds of frailty — and frailty, in turn, was linked to an increased likelihood of prolonged hospital stays. METHODOLOGY: Researchers evaluated the association between nutritional status and frailty among patients with chronic HF and examined whether these factors influenced the length of hospital stay. They included 200 patients aged 60 years or older (mean age, 72.28 years; 70.5% men) who had at least 6-month history of HF, were classified as New York Heart Association functional classes II-IV, and were hospitalised for HF at a hospital in Poland between September 2022 and June 2023. Between 24 and 48 hours after admission, once patients were clinically stabilised, nutritional status was evaluated using the Mini Nutritional Assessment, and frailty was assessed using the Fried phenotype criteria. TAKEAWAY: Overall, 63.5% of patients had adequate nutritional status, 35% were at risk for malnutrition, and 1.5% were malnourished; 65% of patients were categorised as frail and 35% were categorised as pre-frail. Frailty was most common in patients who were malnourished (100%), followed by those who were at risk for malnutrition (78.57%), and least prevalent in those with proper nutrition (56.69%; P = .002). Being at risk for malnutrition or undernutrition was associated with a 5.885-fold increase in odds of frailty (P < .001). Patients classified as frail were a little over four times more likely to have a hospital stay exceeding 5 days than those classified as pre-frail (P = .012). IN PRACTICE: "The findings underscore the need for integrating comprehensive nutritional assessments into the routine care of CHF [chronic HF] patients. Interventions targeting malnutrition could be crucial in reducing the incidence of frailty and improving the overall prognosis in these patients," the researchers concluded. SOURCE: This study was led by Katarzyna Lomper, Wroclaw Medical University, Wrocław, Poland. It was published online on August 11, 2025, in ESC Heart Failure. LIMITATIONS: Patients were included from only one cardiology department, which may not be representative of a broader population. Only patients aged 60 years or older were enrolled, limiting generalisability to those who were younger or had different health statuses. Specific data on congestion at the time of evaluation were not systematically collected, potentially affecting the interpretation of factors influencing the length of hospital stay. DISCLOSURES: This study received funding from the National Science Centre, Poland. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
